The pharmaceutical company Sanofi announced on March 16 that will reduce up to 78% the priceor its most prescribed insulin product in the United States, joining two other major producers of the drug that have announced similar measures in recent weeks.
Sanofi will invest 19 million dollars in Mexico in research and therapies
Read more
In a statement, the company also said it will impose a price maximum of 35 dollars a month to insulin for people with private health insurance.
Sanofi’s decision comes after pharmaceutical companies Eli Lilly and Novo Nordisk announced similar measuresgiven the pressure from the Government of President Joe Biden for companies to reduce the price of insulin, a medicine that is much more expensive in the United States than in other countries.
In a statement, President Biden referred to the pharmaceutical company’s announcement, noting that it is the “last company to recognize than charging hundreds of dollars for insulin that costs ten dollars to produce That’s wrong“.
The president also took the opportunity to ask Congress to pass a law that allows all Americans to obtain insulin at $35 a month.
The Inflation Reduction Act, approved by Congress last year, establishes that those over 65 years of age who benefit from the public health coverage program “Medicare” will pay a maximum $35 a month for insulin.
Pharmaceutical Eli Lilly reduces its insulin prices in the US by 70%
Read more
According to the American Diabetes Association, people diagnosed with diabetes incur on average twice the medical expenses of those who do not have the disease.
Specifically, diabetics in the US spend an average of $16,752 per year on healthcare, of which $9,601 are directly related to diabetes-related out-of-pocket costs.
In the United States, about 30 million people have diabetes, of whom 7 million need insulin daily, according to the American Diabetes Association.
